# ARS Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ars-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.ars-pharma.com
- Total disclosed funding: $75M
- Latest round: Series D (Aug 31, 2021)
- Investors on record: 2

## About

Based in California, US, and founded in 2015 by Richard Lowenthal and Sarina Tanimoto, ARS Pharmaceuticals, Inc. operates as a pharmaceutical company that specializes in the development of drugs for allergy treatment. In April 2023, Araris Biotech AG, a portfolio company of 4BIO Capital Partners, BB Pureos Bioventures, etc acquired ARS Pharmaceutical’s Nectin-4 Antibody from ARS Pharmaceuticals, Inc. In July 2022, Silverback Therapeutics, Inc., a portfolio company of Fidelity Investments, OrbiMed Advisors, Nantahala Capital Management, Nextech and RA Capital, agreed to merge into ARS Pharmaceuticals, Inc. and will continue to operate under the name ARS Pharmaceuticals, Inc, which will trade on the Nasdaq Capital Market under the SPRY ticker.

 ARS Pharmaceuticals is a biopharmaceutical firm with a primary focus on developing a potentially first-of-its-kind product called neffy (previously known as ARS-1), which can be used for the emergency treatment of Type I allergic reactions such as anaphylaxis. neffy is a combination of epinephrine and intravail, an absorption enhancer that enables it to be administered as a reliable and rapidly absorbed nasal spray with injection-like effectiveness, in a small, portable, and user-friendly form.

## Funding rounds

- Series D, Aug 31, 2021, $55M — Deerfield Management, RA Capital Management
- Series C, Sep 14, 2018, $20M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D